Post-Operative Nausea and Vomiting in Children Submitted to Strabismus Surgery
Primary Purpose
Anesthesia, Strabismus, PONV
Status
Unknown status
Phase
Phase 3
Locations
Brazil
Study Type
Interventional
Intervention
Palonosetron
Dexamethasone
Sponsored by
About this trial
This is an interventional prevention trial for Anesthesia focused on measuring Anesthesia, Strabismus, PONV
Eligibility Criteria
Inclusion Criteria:
- Children undergoing elective strabismus surgery
- Physical state according to an American Society of Anesthesiologists (ASA) I and II
Exclusion Criteria:
- Children nor involved in surgery
- Participation in another study in the last month
- Previous history of PONV
- Occurrence of episodes of nausea or vomiting in the last 24 hours before surgery
- Chronic use of corticosteroids
- Previous history of motion sickness
- Use of psychoactive drugs or any other medicine with an antiemetic effect;
- Known hypersensitivity to any study medication
- Severe diseases in organs such as kidney, liver, lung, heart, brain and bone marrow
Sites / Locations
- Hospital Universitário Antonio PedroRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Group P
Group D
Arm Description
During general anesthesia patients will receive a single intravenous dose of palonosetron 1 mcg.Kg-1.
During general anesthesia patients will receive a single intravenous dose of dexamethasone 0.2 mg.Kg-1.
Outcomes
Primary Outcome Measures
Vomiting
Quantify the frequency of individual episodes of vomiting at the first 48 hours after surgery.
Secondary Outcome Measures
Vomiting
Quantify the frequency of individual episodes of vomiting at the first 24 hours after surgery.
Vomiting
Quantify the frequency of individual episodes of vomiting at the first 6 hours after surgery.
Vomiting
Quantify the frequency of individual episodes of vomiting at the first 2 hours after surgery.
Nausea
Quantify the frequency of episodes of nausea at the first 48 hours after surgery.
Nausea
Quantify the frequency of episodes of nausea at the first 24 hours after surgery.
Nausea
Quantify the frequency of episodes of nausea at the first 6 hours after surgery.
Nausea
Quantify the frequency of episodes of nausea at the first 2 hours after surgery.
Check adverse effects
Check the frequency of adverse events (headache, dizziness, drowsiness).
Treatment cost
Price evaluation of antiemetic drugs.
Response to medication
Quantify the number of complete responders (individuals who did not have an episode of PONV and did not require rescue medication).
Full Information
NCT ID
NCT04060771
First Posted
April 18, 2019
Last Updated
August 16, 2019
Sponsor
Universidade Federal Fluminense
1. Study Identification
Unique Protocol Identification Number
NCT04060771
Brief Title
Post-Operative Nausea and Vomiting in Children Submitted to Strabismus Surgery
Official Title
Prospective, Double-blind Study Comparing Palonosetron and Dexamethasone in the Prophylaxis of Post-Operative Nausea and Vomiting in Children Submitted to Strabismus Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
August 2019
Overall Recruitment Status
Unknown status
Study Start Date
August 1, 2018 (Actual)
Primary Completion Date
November 1, 2019 (Anticipated)
Study Completion Date
July 1, 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universidade Federal Fluminense
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Background: Postoperative nausea and vomiting (PONV) is one of the main causes of patient and family dissatisfaction, which may delay the onset of oral intake and postpone discharge. In pediatric patients, the incidence of PONV is high, and in some studies it can reach values of 70%. Strabismus surgery is considered an independent risk factor for PONV. Palonosetron is a second generation antiemetic drug, 5-hydroxytryptamine receptor antagonist, with a long half-life, which allows single dose administration and has been shown to be safe and effective in the treatment of chemotherapy induced nausea and vomiting, and has been used with satisfactory results in the prophylaxis of PONV in adult and pediatric patients. Studies involving palonosetron are still scarce.
Detailed Description
Prospective, double-blind study comparing Palonosetron and Dexamethasone in the prophylaxis of Post-Operative Nausea and Vomiting in children submitted to Strabismus surgery ABSTRACT Background: Postoperative nausea and vomiting (PONV) is one of the main causes of patient and family dissatisfaction, which may delay the onset of oral intake and postpone discharge. In pediatric patients, the incidence of PONV is high, and in some studies it can reach values of 70%. Strabismus surgery is considered an independent risk factor for PONV. Palonosetron is a second generation antiemetic drug, 5-hydroxytryptamine receptor antagonist, with a long half-life, which allows single dose administration and has been shown to be safe and effective in the treatment of chemotherapy induced nausea and vomiting, and has been used with satisfactory results in the prophylaxis of PONV in adult and pediatric patients. Studies involving palonosetron are still scarce.
Objective: The study aims to compare the incidence of PONV after intravenous administration of palonosetron or dexamethasone in pediatric patients undergoing elective strabismus surgery under general anesthesia.
Materials and Methods: This prospective, double-blind study consist of 80 patients of both genders, classified as ASA grade I and II, ranging in age from 2 to 15 years, scheduled for elective strabismus surgery at Hospital Universitário Antonio Pedro(HUAP), after consent by their parents. Patients will be randomized into two groups of 40 patients each. Group P will receive intravenous dose of palonosetron (1 mg.kg-1), and Group D will receive dexamethasone (0.2 mg.kg-1) after induction of anesthesia. Pacients will be observed for 6 hours before discharge and post-discharge symptoms will be assessed through telephone survey after 24 and 48 hours. At the end of the study, results will be compiled and statistical analysis will be done by using Mann-Whitney test, Chi-squared test and Fisher test.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anesthesia, Strabismus, PONV
Keywords
Anesthesia, Strabismus, PONV
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Patients will be divided between two groups, Group P will receive single dose of palonosetron whereas Group D will receive a single dose of dexamethasone during general anesthesia.
Masking
ParticipantInvestigator
Masking Description
Double-blinded
Allocation
Randomized
Enrollment
80 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Group P
Arm Type
Experimental
Arm Description
During general anesthesia patients will receive a single intravenous dose of palonosetron 1 mcg.Kg-1.
Arm Title
Group D
Arm Type
Active Comparator
Arm Description
During general anesthesia patients will receive a single intravenous dose of dexamethasone 0.2 mg.Kg-1.
Intervention Type
Drug
Intervention Name(s)
Palonosetron
Other Intervention Name(s)
Prophylactic
Intervention Description
prophylaxis of postoperative nausea and vomiting
Intervention Type
Drug
Intervention Name(s)
Dexamethasone
Other Intervention Name(s)
Prophylactic
Intervention Description
prophylaxis of postoperative nausea and vomiting
Primary Outcome Measure Information:
Title
Vomiting
Description
Quantify the frequency of individual episodes of vomiting at the first 48 hours after surgery.
Time Frame
48 hours postoperative
Secondary Outcome Measure Information:
Title
Vomiting
Description
Quantify the frequency of individual episodes of vomiting at the first 24 hours after surgery.
Time Frame
24 hours postoperative
Title
Vomiting
Description
Quantify the frequency of individual episodes of vomiting at the first 6 hours after surgery.
Time Frame
6 hours postoperative
Title
Vomiting
Description
Quantify the frequency of individual episodes of vomiting at the first 2 hours after surgery.
Time Frame
2 hours postoperative
Title
Nausea
Description
Quantify the frequency of episodes of nausea at the first 48 hours after surgery.
Time Frame
48 hours postoperative
Title
Nausea
Description
Quantify the frequency of episodes of nausea at the first 24 hours after surgery.
Time Frame
24h hours postoperative
Title
Nausea
Description
Quantify the frequency of episodes of nausea at the first 6 hours after surgery.
Time Frame
6h hours postoperative
Title
Nausea
Description
Quantify the frequency of episodes of nausea at the first 2 hours after surgery.
Time Frame
2h hours postoperative
Title
Check adverse effects
Description
Check the frequency of adverse events (headache, dizziness, drowsiness).
Time Frame
48 hours postoperative
Title
Treatment cost
Description
Price evaluation of antiemetic drugs.
Time Frame
48 hours postoperative
Title
Response to medication
Description
Quantify the number of complete responders (individuals who did not have an episode of PONV and did not require rescue medication).
Time Frame
48 hours postoperative
10. Eligibility
Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
15 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Children undergoing elective strabismus surgery
Physical state according to an American Society of Anesthesiologists (ASA) I and II
Exclusion Criteria:
Children nor involved in surgery
Participation in another study in the last month
Previous history of PONV
Occurrence of episodes of nausea or vomiting in the last 24 hours before surgery
Chronic use of corticosteroids
Previous history of motion sickness
Use of psychoactive drugs or any other medicine with an antiemetic effect;
Known hypersensitivity to any study medication
Severe diseases in organs such as kidney, liver, lung, heart, brain and bone marrow
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alexandra R Assad, MD, MSc, PhD
Phone
5521999859746
Email
Alexandraassad@hotmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Ismar L Cavalcanti, MD, MSc, PhD
Phone
5521999822993
Email
Ismarcavalcanti@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Júlio CA Moreira, MD
Organizational Affiliation
Hospital Universitário Antonio Pedro
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Universitário Antonio Pedro
City
Niterói
State/Province
Rio De Janeiro
ZIP/Postal Code
24033900
Country
Brazil
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Júlio CA Moreira, Md
12. IPD Sharing Statement
Learn more about this trial
Post-Operative Nausea and Vomiting in Children Submitted to Strabismus Surgery
We'll reach out to this number within 24 hrs